SEC Form 4 · accession 0001553878-17-000070
ALNYLAM PHARMACEUTICALS, INC. · ALNY
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Laurie Keating
Officer — SVP, GC and Secretary
Period of report
Dec 1, 2017
Accepted (ET)
Dec 5, 2017 · 5:47 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001178670
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Dec 1, 2017 | M | 30,000 | $77.40 | A | 41,500 | D | |
| Common StockF2 | Dec 1, 2017 | S | 2,800 | $133.37 | D | 38,700 | D | |
| Common StockF3 | Dec 1, 2017 | S | 3,801 | $134.59 | D | 34,899 | D | |
| Common StockF4 | Dec 1, 2017 | S | 7,500 | $135.56 | D | 27,399 | D | |
| Common StockF5 | Dec 1, 2017 | S | 9,700 | $136.50 | D | 17,699 | D | |
| Common StockF6 | Dec 1, 2017 | S | 6,199 | $137.29 | D | 11,500 | D | |
| Common StockF7 | holding | — | — | — | 257 | I | By Managed Account |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F8 | $77.40 | Dec 1, 2017 | M | 30,000 | D | — | Sep 22, 2024 | Common Stock | 30,000 | 95,000 | D |
Explanation of responses
- F1All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 22, 2017.
- F2Sale prices ranged from $132.90 to $133.74.
- F3Sale prices ranged from $133.95 to $134.92.
- F4Sale prices ranged from $134.99 to $135.93.
- F5Sale prices ranged from $136.00 to $136.95.
- F6Sale prices ranged from $137.04 to $137.73.
- F7The reporting person owns 257 shares of ALNY common stock under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program.
- F8The stock option vests as to 25% of the shares on the first anniversary of the date of the stock option grant and as to an additional 6.25% of the shares each successive three month period thereafter.